Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial
Article first published online: 3 JAN 2013
Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Volume 108, Issue 4, pages 751–761, April 2013
How to Cite
Coffin, P. O., Santos, G.-M., Das, M., Santos, D. M., Huffaker, S., Matheson, T., Gasper, J., Vittinghoff, E. and Colfax, G. N. (2013), Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction, 108: 751–761. doi: 10.1111/add.12073
- Issue published online: 18 MAR 2013
- Article first published online: 3 JAN 2013
- Accepted manuscript online: 27 NOV 2012 05:03PM EST
- Manuscript Accepted: 15 NOV 2012
- Manuscript Revised: 16 OCT 2012
- Manuscript Received: 16 AUG 2012
- a National Institute on Drug Abuse. Grant Number: 1 R01 DA023387-01
- sexual risk behaviors
To test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo.
Participants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse counseling.
The trial was conducted from January 2009 to March 2012 at the San Francisco Department of Public Health.
Ninety actively using, methamphetamine-dependent, sexually active adults were recruited from community venues.
The primary outcome was regression estimated reductions in weekly methamphetamine-positive urines. Secondary outcomes were study medication adherence [by self-report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine.
Participant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty-three per cent of follow-up visits and final visits were completed. By intent-to-treat, participants assigned to aripiprazole had similar reductions in methamphetamine-positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66–1.19, P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self-report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self-report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05).
Compared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.